Compare Tesla, Inc. (TSLA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs Viatris Inc — how do they compare? Tesla, Inc. trades at $383.43 (market cap $1.48T), while Viatris Inc trades at $17.63 (market cap $20.03B). The key difference: Tesla, Inc. is far larger — about 73.9× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tesla, Inc. for 88 Days and Viatris Inc for 57 Days on average.
| TSLA | VTRS | |
|---|---|---|
Market Cap | $1.48T | $20.03B |
Volume | 28,215,427 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $18.27 |
52-Week Low | $298.16 | $9.74 |
Typical Hold Time | 88 Days | 57 Days |
Enterprise Value | $1.45T | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla trades at $382.89, up 1.4% with a bullish technical signal from moving averages. The company shows mixed fundamentals with declining profit margins (3.67% net income margin) despite recent earnings beats, while valuation ratios remain elevated (P/E 347). Recent news highlights regulatory approval for driver-assistance software in Europe and a potential cheaper EV model, though Q2 2026 earnings missed expectations. Cash flow trends show consistent operational strength but heavy investment outflows.
Tesla's outlook balances innovation leadership in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441 suggests 15% upside, but investors face volatility from competitive pressures and reliance on future technology adoption. The stock's performance hinges on delivering growth beyond traditional automotive segments.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
